[go: up one dir, main page]

NO20070330L - Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser - Google Patents

Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser

Info

Publication number
NO20070330L
NO20070330L NO20070330A NO20070330A NO20070330L NO 20070330 L NO20070330 L NO 20070330L NO 20070330 A NO20070330 A NO 20070330A NO 20070330 A NO20070330 A NO 20070330A NO 20070330 L NO20070330 L NO 20070330L
Authority
NO
Norway
Prior art keywords
methods
treatment
retinal derivatives
visual disorders
derivatives
Prior art date
Application number
NO20070330A
Other languages
English (en)
Other versions
NO339969B1 (no
Inventor
Krzysztof Palczewski
Mathew Batten
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of NO20070330L publication Critical patent/NO20070330L/no
Publication of NO339969B1 publication Critical patent/NO339969B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/10—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/06—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms
    • C07C403/12—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by singly-bound oxygen atoms by esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Preparater av og fremgangsmåter for anvendelse av syntetiske retinalderivater som retinoiderstatninger og opsinagonister er tilveiebrakt.
NO20070330A 2004-06-18 2007-01-17 9-cis-retinalderivat og anvendelse derav ved fremstilling av et medikament eller et farmasøytisk preparat for anvendelse ved behandling av synsforstyrrelser. NO339969B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58088904P 2004-06-18 2004-06-18
PCT/US2005/021812 WO2006002097A2 (en) 2004-06-18 2005-06-20 Retinal derivatives and methods for the use thereof for the treatment of visual disorders

Publications (2)

Publication Number Publication Date
NO20070330L true NO20070330L (no) 2007-03-15
NO339969B1 NO339969B1 (no) 2017-02-20

Family

ID=35782277

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070330A NO339969B1 (no) 2004-06-18 2007-01-17 9-cis-retinalderivat og anvendelse derav ved fremstilling av et medikament eller et farmasøytisk preparat for anvendelse ved behandling av synsforstyrrelser.

Country Status (27)

Country Link
US (8) US7951841B2 (no)
EP (5) EP2397132B1 (no)
JP (2) JP5166026B2 (no)
KR (4) KR101323122B1 (no)
CN (2) CN102976937B (no)
AU (1) AU2005257997B2 (no)
BR (1) BRPI0511396B1 (no)
CA (2) CA2931917A1 (no)
CY (2) CY1114873T1 (no)
DK (2) DK1765322T3 (no)
ES (4) ES2644984T3 (no)
HK (1) HK1098696A1 (no)
HR (1) HRP20140116T1 (no)
HU (1) HUE036596T2 (no)
IL (4) IL180078A (no)
IN (1) IN2012DN09335A (no)
LT (1) LT2397133T (no)
MX (2) MX359668B (no)
NO (1) NO339969B1 (no)
NZ (2) NZ552080A (no)
PL (2) PL2397133T3 (no)
PT (2) PT1765322E (no)
RS (1) RS53178B (no)
RU (2) RU2408578C2 (no)
SI (2) SI1765322T1 (no)
WO (1) WO2006002097A2 (no)
ZA (1) ZA200700368B (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004222279B2 (en) 2003-03-14 2010-01-21 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
NZ552080A (en) * 2004-06-18 2011-03-31 Univ Washington 9-cis-retinyl esters and uses thereof
ATE404188T1 (de) 2004-06-23 2008-08-15 Sirion Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
NZ554734A (en) * 2004-12-08 2009-03-31 Sirion Therapeutics Inc Methods, Assays And Compositions For Treating Retinol-Related Diseases
CA2657015A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CA2657238A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic disease
US8338394B2 (en) * 2006-10-12 2012-12-25 Case Western Reserve University Methods for treating metabolic diseases
KR101368248B1 (ko) 2007-04-20 2014-03-14 어큐셀라 인코포레이티드 안과 질환 및 장애 치료용 스티레닐 유도체 화합물
CN101969938A (zh) * 2008-02-11 2011-02-09 华盛顿大学 治疗和预防年龄相关视网膜功能障碍的方法
AU2015200520B2 (en) * 2008-02-11 2017-02-09 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US8529907B2 (en) * 2008-04-29 2013-09-10 Nikken Sohonsha Corporation Methods of treating ophthalmic disorders
IN2012DN00352A (no) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
RU2546005C2 (ru) * 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8889660B2 (en) 2010-01-20 2014-11-18 Case Western Reserve University Methods for treating obesity or an obesity related condition
SG184971A1 (en) 2010-04-19 2012-11-29 Quadra Logic Tech Inc Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
EP2635109A4 (en) * 2010-11-05 2014-03-19 Univ Leland Stanford Junior Optically-controlled cns dysfunction
US10226536B2 (en) 2011-11-28 2019-03-12 Case Western Reserve University Polysaccharide therapeutic conjugates
US20150038582A1 (en) * 2012-03-01 2015-02-05 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
WO2013134867A1 (en) * 2012-03-01 2013-09-19 Qlt Inc. Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
JP6449764B2 (ja) 2012-06-07 2019-01-09 ベス イスラエル デアコネス メディカル センター インコーポレイテッド Ｐｉｎ１の阻害のための方法および組成物
US20150119388A1 (en) * 2012-06-15 2015-04-30 The Children's Hospital Philadelphia Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges
WO2015184453A1 (en) 2014-05-30 2015-12-03 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
WO2016145186A1 (en) * 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
KR20190020661A (ko) * 2016-04-28 2019-03-04 스파크 테라퓨틱스, 인코포레이티드 아이소메로하이드롤라아제를 인코딩하는 바이러스 벡터에 대한 상대 효능 검정
WO2023150258A1 (en) * 2022-02-04 2023-08-10 New York University Use of retinoids for treatment of atrial fibrillation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797977A (en) * 1956-01-16 1958-07-09 Hoffmann La Roche Vitamin-a esters and a process for the manufacture thereof
US3196048A (en) 1961-12-19 1965-07-20 Exxon Research Engineering Co Cathode catalyst for fuel cells
US3196078A (en) * 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) * 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) * 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
DE2456959A1 (de) * 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
NZ283658A (en) 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
RU2106843C1 (ru) * 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) * 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
AU5532296A (en) * 1995-04-03 1996-10-23 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids and liposomes
US5620970A (en) * 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
EP0908179A1 (en) * 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) * 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) * 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
CA2373237A1 (en) 2000-03-10 2001-09-20 Insite Vision Incorporated Methods and compositions for treating and preventing posterior segment ophthalmic disorders
US20020028849A1 (en) * 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) * 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
EP1261623B1 (en) 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
WO2002058586A2 (en) 2001-01-26 2002-08-01 Steven Baranowitz Systemic formulations containing beta-carotene and derivatives thereof
GB0103998D0 (en) 2001-02-19 2001-04-04 King S College London Method
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
AU2003210597A1 (en) * 2002-01-18 2003-07-30 Tatton Technologies, Llc. Methods for treating eye disorders
US20030215413A1 (en) * 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
KR20040095250A (ko) 2002-03-29 2004-11-12 맥심 파마수티컬즈 인크. 안내 손상의 치료 및 예방에 사용하기 위한 활성 산소대사물(ｒｏｍ)의 생성 및 방출 억제제의 용도
CN2601278Y (zh) 2003-01-07 2004-01-28 杨天民 自动闭合式排水盖
AU2004222279B2 (en) 2003-03-14 2010-01-21 University Of Washington Retinoid replacements and opsin agonists and methods for the use thereof
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007529434A (ja) 2004-03-17 2007-10-25 ラース マイケル ラーセン， 視覚サイクルの阻害による網膜症の予防
NZ552080A (en) 2004-06-18 2011-03-31 Univ Washington 9-cis-retinyl esters and uses thereof
ATE404188T1 (de) 2004-06-23 2008-08-15 Sirion Therapeutics Inc Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
AU2005287343A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006039551A2 (en) 2004-09-30 2006-04-13 The Regents Of The University Of California Local administration of retinoids to treat deficiencies in dark adaptation
USRE47045E1 (en) 2007-09-12 2018-09-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
CN101969938A (zh) 2008-02-11 2011-02-09 华盛顿大学 治疗和预防年龄相关视网膜功能障碍的方法

Also Published As

Publication number Publication date
NZ552080A (en) 2011-03-31
US20170014368A1 (en) 2017-01-19
JP5596749B2 (ja) 2014-09-24
CN1988898B (zh) 2012-12-26
US9174936B2 (en) 2015-11-03
US9162978B2 (en) 2015-10-20
PT1765322E (pt) 2014-02-05
EP2397131A2 (en) 2011-12-21
EP1765322A2 (en) 2007-03-28
EP2397133A2 (en) 2011-12-21
IL180078A0 (en) 2007-05-15
ES2644981T3 (es) 2017-12-01
WO2006002097A2 (en) 2006-01-05
NZ587006A (en) 2011-12-22
EP2397130B1 (en) 2019-04-03
RU2554003C2 (ru) 2015-06-20
US20190167626A1 (en) 2019-06-06
US20130072556A1 (en) 2013-03-21
EP2397130A2 (en) 2011-12-21
KR20130079669A (ko) 2013-07-10
ES2752924T3 (es) 2020-04-06
KR20140140616A (ko) 2014-12-09
EP2397133A3 (en) 2012-07-11
CA2571049C (en) 2016-08-09
US9169204B2 (en) 2015-10-27
PT2397133T (pt) 2017-10-23
HRP20140116T1 (hr) 2014-03-28
KR101323122B1 (ko) 2013-10-30
AU2005257997A1 (en) 2006-01-05
IL180078A (en) 2014-01-30
EP2397131B1 (en) 2019-09-11
US7951841B2 (en) 2011-05-31
CA2571049A1 (en) 2006-01-05
IN2012DN09335A (no) 2015-08-21
PL2397133T3 (pl) 2018-01-31
RU2007101735A (ru) 2008-07-27
CA2931917A1 (en) 2006-01-05
KR101337321B1 (ko) 2013-12-06
KR20120062946A (ko) 2012-06-14
CN102976937A (zh) 2013-03-20
EP2397132A3 (en) 2012-07-11
DK2397133T3 (en) 2017-10-30
EP2397132B1 (en) 2017-07-26
US9388130B2 (en) 2016-07-12
NO339969B1 (no) 2017-02-20
ZA200700368B (en) 2008-10-29
EP2397133B1 (en) 2017-07-26
US9403765B2 (en) 2016-08-02
SI1765322T1 (sl) 2014-03-31
EP1765322A4 (en) 2008-09-17
CY1114873T1 (el) 2016-12-14
CY1119480T1 (el) 2018-03-07
CN1988898A (zh) 2007-06-27
MXPA06014750A (es) 2007-03-21
EP2397132A2 (en) 2011-12-21
WO2006002097A3 (en) 2006-05-04
RU2010138410A (ru) 2012-03-27
ES2443194T3 (es) 2014-02-18
BRPI0511396A (pt) 2007-12-04
DK1765322T3 (da) 2014-02-10
ES2644984T3 (es) 2017-12-01
RS53178B (en) 2014-06-30
RU2408578C2 (ru) 2011-01-10
IL222347A (en) 2017-08-31
KR101490145B1 (ko) 2015-02-05
MX359668B (es) 2018-10-05
JP5166026B2 (ja) 2013-03-21
US20130079403A1 (en) 2013-03-28
JP2012229234A (ja) 2012-11-22
LT2397133T (lt) 2018-01-10
HK1098696A1 (en) 2007-07-27
EP2397130A3 (en) 2012-10-31
AU2005257997B2 (en) 2012-04-05
KR20070026817A (ko) 2007-03-08
EP1765322B1 (en) 2013-11-06
IL230242A (en) 2015-10-29
JP2008503496A (ja) 2008-02-07
PL1765322T3 (pl) 2014-04-30
US20130072559A1 (en) 2013-03-21
SI2397133T1 (sl) 2017-12-29
US20110288170A1 (en) 2011-11-24
CN102976937B (zh) 2016-12-21
BRPI0511396B1 (pt) 2021-07-27
US20130072560A1 (en) 2013-03-21
HUE036596T2 (hu) 2018-07-30
US10117845B2 (en) 2018-11-06
US20080221208A1 (en) 2008-09-11
IL230241A (en) 2015-06-30
EP2397131A3 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
NO20070330L (no) Retinalderivater og fremgangsmater for anvendelse derav til behandling av synsforstyrrelser
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
NO20092637L (no) Fremgangsmater for behandling
NO20065179L (no) Polysykliske pyridiner som kalsium-kanalmodulatorer
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20083202L (no) ANG2- og VEFG-inhibitorkombinasjoner
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
NO20062878L (no) Isoflavonoidpromedikamenter, terapeutiske sammensetninger derav og terapeutiske fremgangsmater som innbefatter de samme
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
TW200509896A (en) Analeptic and drug combinations
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CY1112121T1 (el) ΠΑΡΑΓΩΓΑ ΤΩΝ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-[1,2-α]-ΠΥΡΑΖΙΝ-6-ΚΑΡΒΟΞΑΜΙΔΙΩΝ ΚΑΙ ΤΩΝ 2,3,4,5-ΤΕΤΡΑΫΔΡΟΠΥΡΡΟΛΟ-(1,2-α)-ΔΙΑΖΕΠΙΝ-7-ΚΑΡΒΟΞΑΜΙΔΙΩΝ, Η ΠΑΡΑΣΚΕΥΗ ΤΟΥΣ ΚΑΙ Η ΕΦΑΡΜΟΓΗ ΤΟΥΣ ΣΕ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees